Revolution Medicines’ stock slid 6.3% Thursday after newly released FDA review documents sparked investor unease around ...

After a year of rocky financials and trial readouts, Quince Therapeutics is charting a new path forward and relaunching with ...

With a Friday go-ahead from the FDA, another key piece of Teva’s innovation revamp strategy has fallen into place, further ...

Novartis bought an mRNA-coded autoimmune T-cell engager candidate for up to $7.8 billion, as Shionogi offered $2 billion to ...

Promotional interactions between clinicians and pharmaceutical companies are probably associated with harmful outcomes, ...